Epidemiology you can model
Incidence to treated, cut by mutation, stage, geography. Newborn screening and diagnosis rate as levers — not footnotes.
Indication intelligence
Corporate development and M&A teams in biotech and big pharma do not need another twelve-week landscape. They need the thesis on an indication — epidemiology, treatment, pipeline, price, KOLs, residual unmet need — in time for the next IC.
Typical consulting OA
€100–150k
8–12 weeks. An 80-page deck. Three slides get read.
What the IC actually uses
The thesis
Addressable patients. Residual unmet need. What the next asset is worth.
Aperture Brief
€12–48k
Days, not a quarter. A model you can stress, not a PDF you archive.
The problem
We spent years in life-science strategy consulting writing the same object: scope an asset inside an indication. Competitive landscape. Unmet need. Epidemiology. Pipeline. KOL and patient voice. Then a number.
Clients paid six figures because the alternative was an intern and a messy folder of Evaluate and Citeline exports. What they actually needed, most of the time, was a clean snapshot they could defend in a Tuesday meeting — kill, keep, or bid.
Aperture exists for that meeting. Custom per indication, because Duchenne is not heart failure and a mutation split is not a NYHA split. Interactive, because a static prevalence number is how models go wrong. Cheap enough that Search & Eval can run ten of them a year, not two.
What you get
Incidence to treated, cut by mutation, stage, geography. Newborn screening and diagnosis rate as levers — not footnotes.
Lines, share, price, endpoints, whether anything is actually curative, and the residual unmet need each product leaves on the table.
Phase, modality, pathway, route. Late-stage assets with the endpoint and the last readout, not a logo slide.
KOLs, centres of excellence, clinic networks. The map that tells you where the patients actually sit.
What patient groups and clinicians are arguing about this quarter — access, safety scares, infusion burden, the heart.
Probability of success, time to market, a peak-revenue build you can break. The page Corp Dev opens last and remembers.
Case studies
Duchenne is no longer an empty rare-disease market. It is a crowded, mutation-stratified franchise where the first gene therapy has been safety-reset, exon skippers remain modest, and the residual unmet need has shifted from 'any dystrophin' to 'meaningful, durable function in non-ambulatory and cardiac disease.' The next dollar of Corp Dev value sits in next-gen transfer, oligonucleotide delivery, and cardiomyopathy — not in another weekly IV skipper.
OpenSMA is the rare-disease case study everyone cites — three approved SMN-restoring medicines, newborn screening, infants who now walk. The Corp Dev question in 2026 is no longer 'does the category work?' It is 'where is residual value after Zolgensma, Evrysdi and Spinraza have split the incident pie, and what does the next mechanism have to do?'
OpenATTR-CM is the rare disease that stopped being rare the moment nuclear scintigraphy and tafamidis existed. The market is now a three-way fight — stabilizer (Pfizer tafamidis, BridgeBio acoramidis) versus silencer (Alnylam vutrisiran, Ionis/AZ eplontersen) — with gene editing sitting one readout away from rewriting the peak. For Corp Dev this is a sequencing and share-shift problem, not an epidemiology discovery problem.
OpenSolutions
Snapshot
€12,000
per indication · 5 business days
The exec view Corp Dev actually reads. Enough to kill or keep a conversation.
Brief
€28,000
per indication · 10 business days
The product we expect most Search & Eval teams to buy. A working model, not a PDF.
Mandate
€48,000
per indication · 15 business days
When the asset is live in a process and the IC needs a number, not a narrative.
Aperture Desk retainer — €9,500/ month. A living library. New snapshots on request, existing briefs kept current.
Who we are
Aperture is being built by two life-science strategy consultants. We have written the long version of this product, many times, for corporate development, search & evaluation, and commercial strategy teams.
The method is the same. The cost structure is not. Agents do the first pass across labels, trials, registries and open voice. We review, argue with the model, and sign the thesis.
Snapshot in a week. Brief in ten business days. Mandate when a process is live.
Duchenne is cut by mutation and ambulation. ATTR by genotype and NAC stage. The model follows the disease.
Agents collect. Partners decide what the IC is allowed to believe.